Hepion Pharmaceuticals, Inc.
NASDAQ:HEPA
0.63 (USD) • At close November 4, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Hepion Pharmaceuticals, Inc. |
Symbool | HEPA |
Munteenheid | USD |
Prijs | 0.634 |
Beurswaarde | 3,678,968 |
Dividendpercentage | 0% |
52-weken bereik | 0.553 - 4.47 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D. |
Website | https://www.hepionpharma.com |
An error occurred while fetching data.
Over Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease;
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)